Christian Schantz

This inventor holds 15 USPTO granted patents and 5 published patent applications and 5 EPO patents. Top assignees: Hoffmann-La Roche Inc., Roche Diagnostics Gmbh. Active years: 2001-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christian Schantz. Retrieved from https://idiyas.com/inventor/christian-schantz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 5)

% Patents Active = 33.3

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 56(Granted Patents)

Location History:

Thalhausen, DE (2001)
Munich, DE (2009 - 2013)
Penzberg, GB (2019)
Penzberg, DE (2014 - 2023)

Company Filing History:

14 out of 5,026

Hoffmann-La Roche Inc.

patents

1 out of 488

Roche Diagnostics Gmbh

patents

Years Active: 2001-2023

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11732036 - Antibody that binds to VEGF-A and ANG2 and methods of use (2023-08-22),

2. 10434184 - Anti-TPBG antibodies and methods of use (2019-10-08),

3. 10155970 - Use of an amino acid auxotrophy cured prokaryotic strain for the recombinant production of a polypeptide (2018-12-18),

4. 9926582 - Method for the production of polypeptides in the periplasm of prokaryotic cells (2018-03-27),

5. 9845347 - Alkaline feed (2017-12-19),

6. 9487576 - Method for reduction of 1->2 reading frame shifts (2016-11-08),

7. 9139640 - Shortened tetranectin-apolipoprotein A-1 fusion protein, a lipid particle containing it, and uses thereof (2015-09-22),

8. 8951756 - Alkaline feed (2015-02-10),

9. 8877895 - Prokaryotic expression construct (2014-11-04),

10. 8791063 - Shortened tetranectin-apolipoprotein A-I fusion protein, a lipid particle containing it, and uses thereof (2014-07-29),

11. 8552158 - Method for the production of insulin-like growth factor-1 (2013-10-08),

12. 8476232 - Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) (2013-07-02),

13. 7754448 - Method for the recombinant expression of an N-terminal fragment of hepatocyte growth factor (2010-07-13),

14. 7625996 - Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) (2009-12-01),

15. 6291245 - Host-vector system (2001-09-18),

Title: Christian Schantz: Innovator in Antibody Development

Introduction

Christian Schantz is a prominent inventor based in Penzberg, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 15 patents to his name, Schantz has established himself as a key figure in innovative medical solutions.

Latest Patents

Among his latest patents, Schantz has developed an antibody that binds to VEGF-A and ANG2, along with methods of use. This invention relates to anti-VEGF-A/anti-ANG2 antibodies, specifically in the form of a bispecific Fab fragment, and outlines methods for utilizing these antibodies effectively. Additionally, he has created anti-TPBG antibodies and methods of use, further showcasing his expertise in antibody technology.

Career Highlights

Throughout his career, Schantz has worked with notable companies such as Hoffmann-La Roche Inc. and Roche Diagnostics GmbH. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the field of biotechnology.

Collaborations

Some of his notable coworkers include Friederike Hesse and Erhard Kopetzki. Their collaborative efforts have likely played a role in advancing the innovative projects that Schantz has been involved in.

Conclusion

Christian Schantz is a distinguished inventor whose work in antibody development has made a significant impact in biotechnology. His innovative patents and collaborations highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.